Therapeutic effectiveness of minimal doses of rituximab in a patient with rheumatoid arthritis

International Journal of Immunopathology and Pharmacology

Volumn 24, Issue 1, 2011, Pages 265-267

  Bruzzese, Vincenzo ^a  

^a NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

Author keywords

CD20 depletion; Effectiveness; Minimal dose of rituximab; Rheumatoid arthritis

Indexed keywords

CD20 ANTIGEN; CHLORPHENIRAMINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PARACETAMOL; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; B LYMPHOCYTE; CASE REPORT; DRUG MECHANISM; HUMAN; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; THERAPY EFFECT; DAS28; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; INFUSION RELATED REACTION; LOW DRUG DOSE; LYMPHOCYTE COUNT; SYMPTOM; TREATMENT OUTCOME; TREATMENT RESPONSE; IMMUNOLOGY; LETTER;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; MALE;

EID: 79957806815     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201102400135     Document Type: Article

References (5)

1. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54:2793-806. (Pubitemid 44497758)
2. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:613-20. (Pubitemid 43228639)
3. Bruzzese V, Pepe J. Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (rituximab). Reumatismo 2009; 61:306-8.
4. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocyte leukaemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94:2217-24. (Pubitemid 29467667)
5. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and inadequate response to methotrexate (Study Evaluating Riyuximab's Efficacy in MTX iNadequate rEsponders (SERENE)) . Ann Rheum Dis 2010; 69:1629-35.